Kazia Therapeutics (NASDAQ: KZIA) has announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader designed to selectively eliminate nuclear PD-L1—a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression not addressed by currently approved PD-1/PD-L1 antibodies.
According to Kazia, NDL2 demonstrated reversal of immune exhaustion, suppression of metastatic biology, and enhanced anti-tumor activity, including in combination with anti-PD-1 therapy across multiple preclinical models and patient-derived samples. By applying targeted protein degradation to one of the most clinically validated targets in oncology—PD-L1—Kazia aims to address a fundamental limitation of current immunotherapies while advancing a program aligned with growing strategic interest in protein degraders.
In a statement, John Friend, MD, CEO of Kazia, commented, “The pharmaceutical industry is clearly signalling that targeted protein degradation represents a transformational opportunity in oncology. Recent high-profile acquisitions of preclinical protein degrader programs underscore the strategic value being placed on this modality. What differentiates NDL2 is that we are applying protein degradation to PD-L1 as one of the most clinically validated targets in cancer, while addressing a resistance mechanism not reached by existing therapies. Unlike programs focused on narrow biology, PD-L1 protein degraders offers multiple shots on goal across tumor types and treatment settings, which we believe creates a broad strategic partnering opportunity.”
